Loading...

Circulating Tumor Cells Detected from Angiosarcoma Cancer Patients with use of ApoStream® Technology in a First-of-its-kind Study

2020-07-23T16:17:10-04:00Events, Thought Leadership|

PROMISING RESULTS DERIVED FROM THE PIVOTAL PHASE 3 TAPPAS TRIAL OF TRC105 AND VATRIENT® IN PATIENTS WITH ADVANCED ANGIOSARCOMA

HOUSTON, TX – November 14, 2018 – Precision for Medicine and TRACON Pharmaceuticals (NASDAQ:TCON) announced today the presentation of biomarker results from the TAPPAS phase 3 clinical trial that utilized ApoCell’s proprietary circulating tumor cell (CTC) enrichment system, ApoStream. The study, titled Detection of Endoglin-Expressing CTCs in Patients Enrolled in an Adaptive Enrichment Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS), is the first of its kind to show the detection and capture of CTCs from angiosarcoma cancer patients. Interim study results were presented at the Connective Tissue Oncology Society (CTOS) annual meeting in Rome, Italy. (more…)

Notable Recent Publications and Media Coverage

2020-07-23T16:12:57-04:00Thought Leadership|

PHE in Health Affairs, Value in Health,and more…

Health Affairs Blog Article on Patient-Centered Formularies

PHE Senior Director Jason Shafrin and Director Mark Linthicum published an article on the importance of accounting for patient heterogeneity in formulary design and the potential use of tools to help payers understand and assess patient-centered value.

Patient-Centered Formularies: Steps In The Right Direction, But Challenges Remain. Health Affairs Blog, April 11, 2018.DOI: 10.1377/hblog20180404.510552

Health Affairs Blog Article on Components of Value Frameworks

PHE Scientific Advisor Anupam Jena, along with Lauren Neves and Randy Burkholder, published an article in the Health Affairs Blog on April 16, 2018, on the importance of capturing comprehensive components of the value of medical innovations in value frameworks.

Do Value Frameworks Fully Capture The Value Of Innovation? Health Affairs Blog, April 16, 2018.DOI: 10.1377/hblog20180409.228386

Value in Health Study on the Impact of Improved Mobility

PHE researchers quantified the impact of improved mobility on using PHE’s proprietary microsimulation THEMIS, finding that improvements in mobility are likely to lead to significant reductions in medical expenditures and nursing home utilization and significant increases in employment.

Kabiri M, et al. The Long-Term Health and Economic Value of Improved Mobility among Older Adults in the United States. Value in Health. 2018. In Press.

Pharmaceutical Executive Article on the Role of Pharmaceutical Companies in Value Assessment

PHE’s Ross Maclean and Jeroen Jansen published an article in Pharmaceutical Executiveon the role of pharmaceutical companies in conducting transparent and relevant evaluations of value, advocating an open-source approach to conducting cost-effectiveness evaluations.

Transparent and Relevant Evaluations of Value: An Active Role for Pharma

Load More Posts